BeStock  
Stocks › Biotechnology › ATTO

Attovia Therapeutics ATTO

US equityMarket cap rank #3483Biotechnology
$15.72 −$0.70 (-4.26%)
Market open · Oct 8, 12:30 pm ET · After hours $16.42 0.00%
Open$16.27
Prev close$16.42
Day range$15.48 – $16.38
Volume143.3K
Market cap$717.64M
P/E (TTM)–
Dividend yield–

Ownership & positioning

Who holds it, who is betting against it, and where the big money is moving

Institutional ownership48.6%+48.59 pts vs. prior quarter
Institutions holding10+10 vs. prior quarter
Insider trades (recent)15 buys / 0 sellsNet buying
Short interest1.82% of floatDays to cover 4.0 · as of 15 Sep 2026
Short-sale volume share16.9%5-day average of daily volume

Short-sale volume as % of daily volume

10%20%29%39%Sep '26Sep '26Oct '26

Large-order net flow, last 20 sessions

Net of large-order buying minus selling, in USD. Over this window: −$1.57M (6 inflow days, 14 outflow days).

Net flow by order size, last 20 sessions

−$756.0KSuper−$815.8KBig−$387.9KMid−$684.8KSmall

Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.

The five largest holders on file together own 42.8% of shares outstanding.

Largest holders

  • Frazier Life Sciences Management, LP15.27%
  • venBio LLC9.16%
  • Alamar Biosciences, Inc.7.07%
  • Deep Track Capital, LP7.03%
  • Goldman Sachs Asset Management, L.P.4.31%
  • Sanofi2.37%
  • Redmile Group, LLC2.15%
  • Tao Fu1.20%

By investor type

  • VC/PE Fund31.45%
  • Public Company10.47%
  • Mutual Fund4.51%
  • Hedge Fund2.15%
  • Individual/Insider1.58%

Reported short interest has risen from 1.19% to 1.82% of float over the last 3 biweekly reports (14 Aug 2026 to 15 Sep 2026).

Recent institutional activity

HolderTypePeriodShare changeNew stake
Vanguard Capital Management, LLC Mutual Fund 2026/Q3 +90,644 0.2%
Vanguard Portfolio Management, LLC Mutual Fund 2026/Q3 +2,430 0.0%
Deep Track Capital, LP VC/PE Fund 2026/Q3 +3,207,138 7.0%
Frazier Life Sciences Management, LP VC/PE Fund 2026/Q3 +6,968,703 15.3%
venBio LLC VC/PE Fund 2026/Q3 +4,181,367 9.2%
Sanofi Public Company 2026/Q3 +1,082,855 2.4%
Redmile Group, LLC Hedge Fund 2026/Q3 +982,854 2.2%
Alamar Biosciences, Inc. Public Company 2026/Q3 +3,229,279 7.1%
Goldman Sachs Asset Management, L.P. Mutual Fund 2026/Q3 +1,967,074 4.3%
Tao Fu Individual/Insider 2026/Q3 +548,558 1.2%
The Goldman Sachs Group, Inc. Public Company 2026/Q3 +468,567 1.0%
Petter Veiby Individual/Insider 2026/Q3 +104,952 0.2%
Angie You Individual/Insider 2026/Q3 +52,852 0.1%
Hubert Chen Individual/Insider 2026/Q3 +2,960 0.0%
Zaneta Odrowaz Individual/Insider 2026/Q3 +11,116 0.0%

Institutional buy/sell activity by reporting period, largest moves first.

Insider transactions

DateInsiderTitleTransactionSharesPriceHeld after
5 Aug 2026 Sanofi Private Acquisition +300,000 $17.00 1,082,855
5 Aug 2026 Sanofi Derivative Exercise and Retained +782,855 – 1,082,855
5 Aug 2026 Redmile Group, LLC Private Acquisition +200,000 $17.00 982,854
5 Aug 2026 Redmile Group, LLC Derivative Exercise and Retained +782,854 – 782,854
5 Aug 2026 venBio LLC Private Acquisition +382,352 $17.00 4,181,367
5 Aug 2026 venBio LLC Derivative Exercise and Retained +3,799,015 – 4,181,367
5 Aug 2026 Deep Track Capital, LP Derivative Exercise and Retained +1,957,138 – 1,957,138
5 Aug 2026 Frazier Life Sciences Management, LP Private Acquisition +588,235 $17.00 6,154,213
5 Aug 2026 Frazier Life Sciences Management, LP Derivative Exercise and Retained +5,490,629 – 6,154,213
4 Aug 2026 Goldman Sachs Asset Management, L.P. Open Market Derivative Acquisiti +105,807 – 105,807
3 Aug 2026 Sanofi Initial Statement of Beneficial +0 – 782,855
3 Aug 2026 Mitchell Gold Independent Director Other Derivative Acquisition +27,000 $17.00 27,000
3 Aug 2026 Mitchell Gold Independent Director Initial Statement of Beneficial +0 – 19,913
3 Aug 2026 Angie You Independent Director Other Derivative Acquisition +27,000 $17.00 27,000
3 Aug 2026 John Smither Independent Director Initial Statement of Beneficial +0 – 72,792
3 Aug 2026 Hubert Chen Chief Medical Officer Other Derivative Acquisition +140,000 $17.00 140,000
3 Aug 2026 Broad Street Principal Investments, L.L.C. Initial Statement of Beneficial +0 – 855,179
3 Aug 2026 Tao Fu Chief Executive Officer Initial Statement of Beneficial +0 – 803,436
3 Aug 2026 Alamar Biosciences, Inc. Initial Statement of Beneficial +0 – 3,229,278
3 Aug 2026 Zaneta Odrowaz Chief Business Officer, Treasurer & Secretary Other Derivative Acquisition +140,000 $17.00 140,000

From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.

Short interest, by report

Report dateShares short% of floatDays to cover
15 Sep 2026 831,090 1.8% 4.0
31 Aug 2026 648,541 1.5% 3.1
14 Aug 2026 511,865 1.2% 1.0

Discussion

No comments yet — be the first to weigh in on ATTO.

Leave a comment

Scroll to Top